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The pharmacokinetics of tacrolimus after first and repeated application of 0.1% tacrolimus ointment were evaluated
in 39 children, aged 6–12 y, with moderate to severe atopic dermatitis. The patients were grouped according to the
size of the affected body surface area to be treated: Group 1p1500 cm2; Group 2 41500 cm2p3000 cm2; Group 3
43000 cm2p5000 cm2. Serial blood samples to calculate pharmacokinetic parameters taken on Day 1 (first oint-
ment application) and Day 14 (last application) showed minimal systemic exposure to tacrolimus. Overall, 92% of
the blood samples assayed contained tacrolimus concentrations below 1 ng per mL and 17% of samples were
below 0.025 ng per mL, the lower limit of quantification. Systemic exposure to tacrolimus varied between patients
and tended to increase proportionally as the size of the treated body surface area increased. Absorption decreased
with time as the skin lesions healed and there was no evidence of systemic accumulation. The mean apparent half-
life of tacrolimus (t1/2, z) was 66  27 h (range 19–125 h). Most patients experienced substantial clinical improvement
in their atopic dermatitis. There were no clinically relevant changes in laboratory values, and the most frequently
reported adverse event was skin burning, which resolved quickly as the skin condition improved.
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Atopic dermatitis is a common chronic inflammatory skin
disorder that is estimated to occur in 10%–15% of children
in developed countries (Kristal and Klein, 2000). The disease
is characterized by intense itching and eczematous lesions
and although the exact pathogenesis is unknown, it is rec-
ognized that IgE-mediated reactions (Bos et al, 1994) and
elevated eosinophil levels (Kapp, 1993) are involved in
causing inflammation. Topical corticosteroids are the usual
treatment for atopic dermatitis (Goerz and Lehmann, 1991),
but prolonged application can be associated with local and
systemic side effects (Lubach et al, 1989; Matsuda et al,
2000). Research in this therapeutic area has therefore fo-
cused upon finding an alternative anti-inflammatory agent
that is efficacious, well-tolerated, and can be used safely in
the long-term.
Tacrolimus is a calcineurin inhibitor (Dumont, 2000) that
prevents the dephosphorylation of the transcription factor
necessary for the expression of inflammatory T cell cyto-
kines, such as IL-2, IL-3, TNF-a, and IL-4 (Goto et al, 1991).
A topical formulation of tacrolimus was developed with the
aim of delivering the active ingredient directly to the in-
flamed sites in the skin while minimizing systemic exposure
to tacrolimus (Undre, 2003).
Studies investigating the different concentrations of ta-
crolimus ointment (0.03%, 0.1%, 0.3%) applied to children
with moderate to severe atopic dermatitis have demon-
strated that the ointment is extremely efficacious (Alaiti et al,
1998; Boguniewicz et al, 1998; Kang et al, 2001; Paller et al,
2001). In a 12-wk study of 351 children treated twice daily
with either 0.03% or 0.1% tacrolimus ointment, no meas-
urable tacrolimus concentrations were detected in 90% of
the blood samples collected. The mean and median tacro-
limus blood concentrations were p2.28 ng per mL (Paller
et al, 2001), and these blood levels are substantially lower
than those measured in pediatric liver transplant patients
administered tacrolimus systemically. In this study, we eval-
uated the systemic exposure to tacrolimus following first
and repeated applications of 0.1% tacrolimus ointment to
different sizes of treatment area in children with moderate to
severe atopic dermatitis. The clinical efficacy and safety of
the 0.1% tacrolimus ointment were also assessed during
the 2-wk study period.
Results
Demographic and baseline characteristics Demographic
and baseline characteristics were similar for all three treat-
ment groups (Table I). In Group 1, 12 patients had moderate
atopic dermatitis at baseline and four patients had severeAbbreviation: AUC, area under the curve
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atopic dermatitis. In Groups 2 and 3, two patients in both
groups had moderate atopic dermatitis whereas 12 and
seven patients, respectively, had severe atopic dermatitis at
baseline.
Patient disposition Two patients withdrew from the study
prior to active treatment. Fifteen patients did not apply the
ointment as defined in the protocol and were consequently
excluded from the study. A further five patients were with-
drawn because of incomplete pharmacokinetic profiles. The
evaluable population therefore comprised 39 patients:
Group 1 p1500 cm2 (N¼ 16); Group 2 41500 to p3000
cm2 (N¼14); Group 3 43000 to p5000 cm2 (N¼9).
Treatment area and tacrolimus dosage The mean sizes
of treatment areas are shown in Table I. On Day 1 (Profile 1),
the mean dose of tacrolimus administered was 0.007,
0.013, and 0.016 mg per kg, for Groups 1, 2, and 3, re-
spectively, whereas on Day 14 (Profile 2), the respective
mean tacrolimus doses administered were 0.006, 0.012,
and 0.014 mg per kg.
Pharmacokinetic parameters In general, the systemic ex-
posure to tacrolimus following application of 0.1% ta-
crolimus ointment was low and highly variable (Fig 1a and
b). Overall, 92% of all the blood samples assayed contained
tacrolimus concentrations below 1 ng per mL and 17% of
samples were below 0.025 ng per mL, the lower limit of
quantification of the assay. Compared with pediatric liver
transplant patients administered an oral dose of 0.15 mg
per kg per 12 h, the tacrolimus blood levels measured on
Days 1 and 14 in the pediatric atopic dermatitis patients
were minimal (Fig 2).
There was a trend for the systemic exposure to ta-
crolimus to increase as the size of the treated affected body
surface area increased (Table II). On Day 1, the mean area
under the curve (AUC0–24) values for Groups 1, 2, and 3
were 5.17, 17.48, and 11.03 ng h per mL, respectively. The
corresponding mean values on Day 14 were 3.34, 15.44,
and 11.35 ng h per mL. A similar trend was observed with
respect to the mean maximum concentration values (Cmax),
which increased as the size of the treatment area increased.
Evaluation of the mean pre-dose and minimum concentra-
tion measurements (Table III) showed that in all three treat-
ment groups, the concentrations of tacrolimus absorbed
decreased with time as the skin lesions healed, indicating
no systemic accumulation of tacrolimus. There was no ap-
parent trend in times to maximum concentration (tmax)
among the treatment groups or between first and last oint-
ment application. The elimination half-life measured after
Table I. Patient demographics
Treatment group 1
p1500 cm2 (N¼ 16)
Treatment group 2 41500
and p3000 cm2 (N¼ 14)
Treatment group 3 43000 and
p5000 cm2 (N¼ 9)
Male:female (%) 43.8:56.2 64.3:35.7 66.7:33.3
Ethnic group – number of patients (%)
Caucasian 13 (81.3%) 10 (71.4%) 8 (88.9%)
Black 1 (6.2%) 1 (7.1%) 0 (0.0%)
Others 2 (12.5%) 3 (21.4%) 1 (11.1%)
Age in years (mean  SD) 9.8  1.6 8.9  2.2 8.7  1.9
Weight (kg) (mean  SD) 35.8  7.9 31.6  10.7 32.1  7.9
Height (cm) (mean  SD) 141.8  12.8 133.7  16.4 132.2  14.6
Treatment area (cm2) (mean  SD) 1001  443 2317  466 3903  534
% Total body surface area (mean  SD) 24.1  14.8 50.0  14.9 52.8  22.9
% Total body surface area (range) 11–66 24–74 28–94
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Systemic exposure to tacrolimus. (a) Mean tacrolimus blood con-
centration–time profile (Day 1). (b) Mean tacrolimus blood concentra-
tion–time profile (Day 14).
696 HARPER ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
the last application of 0.1% tacrolimus ointment was high-
ly variable among the patients with an overall mean of
66  27 h (range 19–125 h).
Clinical efficacy Most patients experienced substantial
improvement in their clinical condition during the 14-d
treatment period. In Group 1, the percentage decrease be-
tween baseline and Day 14 in the mean size of affected
body surface area was 39.8%, and 36.6% and 40.0%, in
Groups 2 and 3, respectively. With regard to the physician’s
assessment of individual signs and symptoms, the mean
percentage decrease between baseline and Day 14 was
58.3% for Group 1, 48.9% for Group 2, and 55.3% for
Group 3. The physician’s global evaluation of clinical re-
sponse was also very favorable, with 34 of the 39 patients
(87.2%) receiving a rating of at least ‘‘moderate improve-
ment’’ (i.e., X50% improvement).
Adverse events Pruritus and skin burning were the most
frequently reported adverse events. In Group 1, four pa-
tients (25%) reported skin burning and pruritus, respective-
ly, whereas in Group 2, one patient (7%) experienced skin
burning and two patients (14%) had pruritus. None of the
patients in Group 3 reported skin burning, but two patients
(7%) did experience pruritus. In all of these patients, skin
irritation was mild to moderate in severity, resolved quickly,
and did not result in the discontinuation of treatment.
No clinically relevant changes in laboratory assessments
were observed.
Discussion
Despite the potential concern of applying an ointment con-
taining a calcineurin inhibitor to children with atopic der-
matitis, these data indicate clearly that although tacrolimus
is absorbed into the systemic circulation following topical
application, the amount absorbed as measured by AUC0–24
is low and highly variable. The extent of systemic exposure
tended to increase as the size of the treatment area in-
creased, but the highest blood level recorded in the atopic
dermatitis patients during the study was only around 3% of
that measured in liver transplant patients administered ta-
crolimus orally (Wallemacq et al, 1998).
As the study was conducted with children and the
number of blood samples that could be taken was limited,



















Systemic exposure to tacrolimus in pediatric atopic dermatitis
patients compared with pediatric transplant patients. Mean area
under the curve of tacrolimus in pediatric patients with moderate to
severe atopic dermatitis treated with 0.1% tacrolimus ointment com-
pared with pediatric liver transplant patients treated with tacrolimus
systemically.
Table II. Pharmacokinetic parameters of tacrolimus in pediatric patients treated with 0.1% tacrolimus ointment
AUC0–24 (ng h per mL)
(mean  SD)




Cmin (ng per mL)
(mean  SD)
Day 1
Group 1 (N¼ 16) 5.17  8.82 0.44  0.76 4 0.12  0.17
Group 2 (N¼ 14) 17.48  25.74 0.99  1.37 23 0.95  1.37
Group 3 (N¼ 9) 11.03  11.88 1.03  1.13 4 0.78  1.18
Day 14
Group 1 (N¼ 16) 3.34  2.50 0.20  0.19 6 0.11  0.08
Group 2 (N¼ 14) 15.44  28.80 0.83  1.34 4 0.59  1.08
Group 3 (N¼ 9) 11.35  8.66 0.98  1.03 2.5 0.41  0.40
AUC, area under the curve.
Table III. Mean pre-dose concentrations and minimum concentrations of tacrolimus (ng per mL) in children treated with 0.1%
tacrolimus ointment
Day 1 (24 h)
(mean  SD)
Day 4 (0 h)
(mean  SD)
Day 14 (0 h)
(mean  SD)
Day 14 (24 h)
(mean  SD)
Group 1 (N¼ 16) 0.12  0.17 0.29  0.28 0.16  0.17 0.11  0.08
Group 2 (N¼ 14) 0.95  1.37 0.96  0.90 0.67  1.12 0.59  1.08
Group 3 (N¼ 9) 0.78  1.18 0.96  1.58 0.32  0.30 0.41  0.40
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the pre-dose concentration on Day 4 was considered as a
measure of exposure on that day. Examination of the pre-
dose concentrations of tacrolimus measured throughout the
study showed that the systemic exposure to tacrolimus
decreased as the skin lesions healed, and that there was
no systemic accumulation despite repeated applications of
ointment over the 14-d treatment period.
The apparent elimination half-life measured after the
last application of ointment was extremely variable and
longer than the systemic half-life measured in healthy sub-
jects administered tacrolimus either orally or intravenously.
This longer elimination half-life is more indicative of a slower
rate of absorption rather than the actual rate of elimina-
tion. This observation, when considered together with the
fact that the AUC0–24 values on Days 1 and 14 were
similar, indicating that there was no accumulation with
repeated application, implies that both the extent
and rate of absorption of tacrolimus decrease as the skin
lesions heal.
The clinical condition of the patients improved consid-
erably during the short treatment period and if the study had
been longer, it is likely we may have seen further improve-
ment and perhaps even disease clearance in several chil-
dren. Although some patients experienced discomfort
because of the burning sensation upon application of the
ointment, the treatment was generally well-accepted by the
children, which is an important aspect with regard to long-
term compliance.
In conclusion, this study confirms that pediatric patients
applying 0.1% tacrolimus ointment have very low systemic
exposure to tacrolimus, and there appears to be little risk of
immunosuppression. Treatment with 0.1% tacrolimus oint-
ment resulted in considerable clinical improvement and is a
viable alternative to corticosteroids in children with moder-
ate to severe atopic dermatitis.
Materials and Methods
Study design This was a multicenter, open, phase II pharmaco-
kinetics study performed in Ireland, Latvia, Spain, and the UK. The
study was conducted in accordance with the ethical principles
described in the Declaration of Helsinki, and the ethics committee
of each study center reviewed the protocol and granted approval
before the start of the study. A screening visit was carried out 7 d
before the baseline visit (Day 1, ointment application).
Patients Following written informed consent from the parent or
guardian, 61 patients, aged 6–12 y with a diagnosis of atopic der-
matitis based on the criteria of Hanifin and Rajka (1980), were
enrolled into the pharmacokinetics study. The patients all had a
grading of moderate to severe atopic dermatitis as defined by the
scoring system of Rajka and Langeland (1989). This technique
separately rates the extent, course, and intensity of the disease on
a scale between one and three and then adds the three individual
scores to determine overall severity (maximum¼ 9). A score of 3–4
represents mild atopic dermatitis, 4.5–7.5 represents moderate
atopic dermatitis, and 8–9 denotes severe disease.
At the Day 1 visit, the body surface area to be treated was
defined by the physician and the patients were allocated to one of
three groups depending upon the size of the affected area to be
treated: Group 1 p1500 cm2; Group 2 41500 to p3000 cm2; and
Group 3 43000 to p5000 cm2. The designated treatment area
remained the same throughout the study irrespective of any clinical
improvement in the skin condition.
Treatment The patients received two applications of 0.1% ta-
crolimus ointment on each day, except for Days 1 and 14 when the
ointment was applied only once. On Days 1, 4, and 14, the oint-
ment was applied in the morning by the investigator whereas all of
the other ointment applications took place at home.
Assessments Pharmacokinetic profiling took place on Days 1, 4
(pre-dose blood sample), and 14. Blood concentration–time pro-
files were obtained by collecting serial blood samples (2.5 mL into
EDTA monovettes). The blood samples were immediately frozen
and stored at 201C before being shipped to the contract research
laboratory. Profile 1 comprised a pre-dose blood sample (0 h) fol-
lowed by samples taken 2, 4, 8, and 24 h after the first application
of ointment on Day 1. Profile 2 consisted of a pre-dose sample and
then samples taken 2, 4, 8, 24, and 96 h after the last ointment
application on Day 14.
The tacrolimus blood concentration was assayed using high-
pressure liquid chromatography with tandem mass spectrometry
detection. Internal standard (32-0-acetyl derivative of tacrolimus
(Fujisawa, Osaka, Japan)) and protein precipitation reagent (aque-
ous zinc sulfate solution (Sigma, Dorset, UK):methanol (Romil,
Cambridge, UK):acetonitrile (Romil) 50:30:20) were added to the
samples. Solid phase extraction (using 18C cartridges (Anachem,
Luton, UK)) of analytes was performed before injection onto the
liquid chromatography mass spectrometer (Sciex API III Plus, Per-
kin-Elmer, Beaconsfield, UK). The lower limit of quantification for
this method was 0.025 ng per mL with a precision, based on the
co-efficient of variation, of less than 21.3% for the lowest QC
sample and less than 14.7% for all other concentrations. All of the
procedures were performed according to OECD-GLP guidelines.
The maximum blood concentration (Cmax), time to attain Cmax
(tmax), minimum concentration (Cmin), and pre-dose blood concen-
tration (C0) were derived directly from the individual blood con-
centration–time profiles. Non-compartmental analysis, using the
computer program PCModfit v1.60, was used to determine the
AUC concentration time curve between 0 and 24 h using the trap-
ezoidal rule (AUC0–24), between 0 and 96 h using the trapezoidal
rule (AUC0–96), and the terminal half-lives (t1/2). As there were no
12 h samples taken, truncated AUC were calculated for the time
period 0–12 h by assuming a log-linear relationship between
the 8 and 24 h concentration points. For the calculation of AUC,
concentrations less than the lower limit of quantification were set
to zero.
The physician’s global evaluation of clinical response and the
physician’s assessment of individual signs and symptoms were
performed on Days 1, 4, 14, and 18 (follow-up visit) to measure the
clinical efficacy of the 0.1% tacrolimus ointment. Safety was as-
sessed by the monitoring of clinical adverse events reported by the
patient or parent or observed by the physician, and any changes
from baseline in the required physical examinations and laboratory
blood tests.
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